JP2018531273A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018531273A5 JP2018531273A5 JP2018520638A JP2018520638A JP2018531273A5 JP 2018531273 A5 JP2018531273 A5 JP 2018531273A5 JP 2018520638 A JP2018520638 A JP 2018520638A JP 2018520638 A JP2018520638 A JP 2018520638A JP 2018531273 A5 JP2018531273 A5 JP 2018531273A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- days
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 60
- 150000001875 compounds Chemical class 0.000 claims 56
- 239000008194 pharmaceutical composition Substances 0.000 claims 42
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 206010024627 liposarcoma Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 238000013329 compounding Methods 0.000 claims 3
- 101150024228 mdm2 gene Proteins 0.000 claims 3
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- -1 toluenesulfonate monohydrate Chemical class 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021043154A JP7192011B2 (ja) | 2015-10-23 | 2021-03-17 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2022195270A JP2023025214A (ja) | 2015-10-23 | 2022-12-07 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2024139510A JP2024164122A (ja) | 2015-10-23 | 2024-08-21 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245632P | 2015-10-23 | 2015-10-23 | |
| US62/245,632 | 2015-10-23 | ||
| PCT/JP2016/081975 WO2017069289A1 (en) | 2015-10-23 | 2016-10-21 | Dosage regimen of mdm2 inhibitor for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021043154A Division JP7192011B2 (ja) | 2015-10-23 | 2021-03-17 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531273A JP2018531273A (ja) | 2018-10-25 |
| JP2018531273A6 JP2018531273A6 (ja) | 2018-12-13 |
| JP2018531273A5 true JP2018531273A5 (enExample) | 2019-12-12 |
| JP6855472B2 JP6855472B2 (ja) | 2021-04-07 |
Family
ID=57349101
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520638A Active JP6855472B2 (ja) | 2015-10-23 | 2016-10-21 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2021043154A Active JP7192011B2 (ja) | 2015-10-23 | 2021-03-17 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2022195270A Pending JP2023025214A (ja) | 2015-10-23 | 2022-12-07 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2024139510A Pending JP2024164122A (ja) | 2015-10-23 | 2024-08-21 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021043154A Active JP7192011B2 (ja) | 2015-10-23 | 2021-03-17 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2022195270A Pending JP2023025214A (ja) | 2015-10-23 | 2022-12-07 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
| JP2024139510A Pending JP2024164122A (ja) | 2015-10-23 | 2024-08-21 | がんを治療するためのｍｄｍ２阻害剤の投与計画 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20180296547A1 (enExample) |
| EP (1) | EP3364972A1 (enExample) |
| JP (4) | JP6855472B2 (enExample) |
| KR (1) | KR20180064540A (enExample) |
| CN (2) | CN113521069A (enExample) |
| HK (1) | HK1253098A1 (enExample) |
| TW (3) | TWI806822B (enExample) |
| WO (1) | WO2017069289A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI697329B (zh) * | 2015-04-13 | 2020-07-01 | 日商第一三共股份有限公司 | 血液癌症治療用之醫藥及其用途 |
| HK1253098A1 (zh) * | 2015-10-23 | 2019-06-06 | Daiichi Sankyo Company, Limited | 用於治疗癌症的mdm2抑制剂的给药方案 |
| US10409015B1 (en) | 2015-12-15 | 2019-09-10 | Optomind Inc. | Optical receiving device including focusing lens and reflector mounted to housing body and collimating lens mounted to housing cover |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| WO2023016977A1 (en) * | 2021-08-09 | 2023-02-16 | Boehringer Ingelheim International Gmbh | Oral composition comprising a mdm2-antagonist for cancer therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE470665T1 (de) * | 2006-03-22 | 2010-06-15 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
| EP2059236A2 (en) * | 2006-08-21 | 2009-05-20 | Synta Pharmaceuticals Corporation | Combination with bis(thiohydrazide amides) for treating cancer |
| JP5438008B2 (ja) * | 2007-09-21 | 2014-03-12 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| TR201807311T4 (tr) * | 2011-03-10 | 2018-06-21 | Daiichi Sankyo Co Ltd | Dispiropirolidin derivesi. |
| WO2013101436A1 (en) * | 2011-12-07 | 2013-07-04 | Duke University | Methods of identifying and using mdm2 inhibitors |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| JP5958208B2 (ja) * | 2012-09-10 | 2016-07-27 | 凸版印刷株式会社 | 包装袋 |
| BR112016004593B1 (pt) * | 2013-09-04 | 2022-12-06 | Daiichi Sankyo Company, Limited | Métodos para reagir um composto, para hidrolisar um composto ou um sal do mesmo, para produzir um composto e para preparar um composto |
| EP3094746A1 (en) * | 2014-01-14 | 2016-11-23 | Daiichi Sankyo Company, Limited | Gene signatures associated with sensitivity to mdm2 inhibitors |
| CN107427501B (zh) * | 2015-02-20 | 2023-12-01 | 第一三共株式会社 | 通过联合使用治疗癌症的方法 |
| TWI697329B (zh) * | 2015-04-13 | 2020-07-01 | 日商第一三共股份有限公司 | 血液癌症治療用之醫藥及其用途 |
| HK1253098A1 (zh) * | 2015-10-23 | 2019-06-06 | Daiichi Sankyo Company, Limited | 用於治疗癌症的mdm2抑制剂的给药方案 |
-
2016
- 2016-10-21 HK HK18112485.7A patent/HK1253098A1/zh unknown
- 2016-10-21 US US15/769,054 patent/US20180296547A1/en not_active Abandoned
- 2016-10-21 TW TW105134053A patent/TWI806822B/zh active
- 2016-10-21 JP JP2018520638A patent/JP6855472B2/ja active Active
- 2016-10-21 WO PCT/JP2016/081975 patent/WO2017069289A1/en not_active Ceased
- 2016-10-21 EP EP16798291.7A patent/EP3364972A1/en active Pending
- 2016-10-21 TW TW113124518A patent/TW202515561A/zh unknown
- 2016-10-21 TW TW112100559A patent/TW202332444A/zh unknown
- 2016-10-21 CN CN202110980773.0A patent/CN113521069A/zh active Pending
- 2016-10-21 CN CN201680061650.4A patent/CN108135892A/zh active Pending
- 2016-10-21 KR KR1020187014440A patent/KR20180064540A/ko not_active Ceased
-
2019
- 2019-03-06 US US16/293,926 patent/US11058673B2/en active Active
-
2021
- 2021-03-17 JP JP2021043154A patent/JP7192011B2/ja active Active
- 2021-05-18 US US17/323,636 patent/US20220071975A1/en active Pending
-
2022
- 2022-12-07 JP JP2022195270A patent/JP2023025214A/ja active Pending
-
2024
- 2024-08-21 JP JP2024139510A patent/JP2024164122A/ja active Pending